Zobrazeno 1 - 10
of 633
pro vyhledávání: '"Andrew J Armstrong"'
Autor:
Jun Li, Stefanie Zschäbitz, Daniel P Petrylak, Margitta Retz, Prabhu Bhagavatheeswaran, Marc-Oliver Grimm, Jose Perez-Gracia, Gwenaelle Gravis, Karim Fizazi, Jeffrey C Goh, Mauricio Burotto, Daniel Castellano, Fred Saad, Andrew J Armstrong, HAKIM MAHAMMEDI, Russell K Pachynski, Louis Lacombe, Diogo Assed Bastos, Steven L McCune, Juan Carlos Vázquez Limón, Edmond M Kwan, Aude Fléchon, David R Shaffer, Neha P Amin, Keziban Ünsal-Kaçmaz, Xuya Wang, Andrea Loehr
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 8 (2022)
Background CheckMate 9KD (NCT03338790) is a non-randomized, multicohort, phase 2 trial of nivolumab plus other anticancer treatments for metastatic castration-resistant prostate cancer (mCRPC). We report results from cohorts A1 and A2 of CheckMate 9K
Externí odkaz:
https://doaj.org/article/47bed5baf90f4a54860bcc0aa14ca352
Autor:
Ramy Sedhom, Santosh Gupta, Yuan Wu, Jason Zhu, Daniele Marin, Michael R Harrison, Landon C Brown, Matthew D Tucker, Eric B Schwartz, Chester Kao, Matthew K Labriola, Rajan T Gupta, Daniel J George, Emmanuel S Antonarakis, Andrew J Armstrong
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Background Low-density lipoprotein receptor-related protein 1b (encoded by LRP1B) is a putative tumor suppressor, and preliminary evidence suggests LRP1B-mutated cancers may have improved outcomes with immune checkpoint inhibitors (ICI).Methods We co
Externí odkaz:
https://doaj.org/article/f6c317e45ad243c18c3fdb3ae41b8601
Autor:
Andrew J Armstrong, Santosh Gupta, Patrick Healy, Gabor Kemeny, Beth Leith, Michael R Zalutsky, Charles Spritzer, Catrin Davies, Colin Rothwell, Kathryn Ware, Jason A Somarelli, Kris Wood, Thomas Ribar, Paraskevi Giannakakou, Jiaren Zhang, Drew Gerber, Monika Anand, Wen-Chi Foo, Susan Halabi, Simon G Gregory, Daniel J George
Publikováno v:
PLoS ONE, Vol 14, Iss 5, p e0216934 (2019)
BackgroundRadium-223 is a targeted alpha-particle therapy that improves survival in men with metastatic castration resistant prostate cancer (mCRPC), particularly in men with elevated serum levels of bone alkaline phosphatase (B-ALP). We hypothesized
Externí odkaz:
https://doaj.org/article/a30bb6a9379947f68513ccbaae968fe8
Autor:
Zoe D. Michael, Srinath Kotamarti, Rohith Arcot, Kostantinos Morris, Anand Shah, John Anderson, Andrew J. Armstrong, Rajan T. Gupta, Steven Patierno, Nadine J. Barrett, Daniel J. George, Glenn M. Preminger, Judd W. Moul, Kevin C. Oeffinger, Kevin Shah, Thomas J. Polascik
Publikováno v:
The World Journal of Men's Health, Vol 41, Iss 3, Pp 631-639 (2023)
Purpose: Prostate cancer (PCa) screening can lead to potential over-diagnosis/over-treatment of indolent cancers. There is a need to optimize practices to better risk-stratify patients. We examined initial longitudinal outcomes of mid-life men with
Externí odkaz:
https://doaj.org/article/dcb8b48249704eb5a9f6ba4e180b1147
Autor:
William Butler, Colin McDowell, Qing Yang, Yiping He, Yue Zhao, J. Spencer Hauck, Yinglu Zhou, Hong Zhang, Andrew J. Armstrong, Daniel J. George, Richard Drake, Jiaoti Huang
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-10 (2023)
Abstract An understanding of the molecular features associated with prostate cancer progression (PCa) and resistance to hormonal therapy is crucial for the identification of new targets that can be utilized to treat advanced disease and prolong patie
Externí odkaz:
https://doaj.org/article/14d23108c7ff44d882b275eaeb03c44d
Autor:
Rashi Jindal, Abheepsa Nanda, Maalavika Pillai, Kathryn E. Ware, Divyoj Singh, Manas Sehgal, Andrew J. Armstrong, Jason A. Somarelli, Mohit Kumar Jolly
Publikováno v:
Computational and Structural Biotechnology Journal, Vol 21, Iss , Pp 1498-1509 (2023)
Advanced prostate cancer patients initially respond to hormone therapy, be it in the form of androgen deprivation therapy or second-generation hormone therapies, such as abiraterone acetate or enzalutamide. However, most men with prostate cancer even
Externí odkaz:
https://doaj.org/article/f5cf7b96175f41dbb8499a06f75362be
Autor:
Mu-En Wang, Jiaqi Chen, Yi Lu, Alyssa R. Bawcom, Jinjin Wu, Jianhong Ou, John M. Asara, Andrew J. Armstrong, Qianben Wang, Lei Li, Yuzhuo Wang, Jiaoti Huang, Ming Chen
Publikováno v:
The Journal of Clinical Investigation, Vol 133, Iss 10 (2023)
Inactivation of the RB1 tumor suppressor gene is common in several types of therapy-resistant cancers, including metastatic castration-resistant prostate cancer, and predicts poor clinical outcomes. Effective therapeutic strategies against RB1-defici
Externí odkaz:
https://doaj.org/article/ec37f663fce84ed8a0ae06648a43113a
Autor:
Kathryn E. Ware, Beatrice C. Thomas, Pelumi D. Olawuni, Maya U. Sheth, Nathan Hawkey, M. Yeshwanth, Brian C. Miller, Katherine J. Vietor, Mohit Kumar Jolly, So Young Kim, Andrew J. Armstrong, Jason A. Somarelli
Publikováno v:
Frontiers in Molecular Biosciences, Vol 10 (2023)
Despite substantial improvements in the treatment landscape of prostate cancer, the evolution of hormone therapy-resistant and metastatic prostate cancer remains a major cause of cancer-related death globally. The mainstay of treatment for advanced p
Externí odkaz:
https://doaj.org/article/1387a5257992495d9a15d49c7db46780
Autor:
Shuang G. Zhao, Jamie M. Sperger, Jennifer L. Schehr, Rana R. McKay, Hamid Emamekhoo, Anupama Singh, Zachery D. Schultz, Rory M. Bade, Charlotte N. Stahlfeld, Cole S. Gilsdorf, Camila I. Hernandez, Serena K. Wolfe, Richel D. Mayberry, Hannah M. Krause, Matt Bootsma, Kyle T. Helzer, Nicholas Rydzewski, Hamza Bakhtiar, Yue Shi, Grace Blitzer, Christos E. Kyriakopoulos, David Kosoff, Xiao X. Wei, John Floberg, Nan Sethakorn, Marina Sharifi, Paul M. Harari, Wei Huang, Himisha Beltran, Toni K. Choueiri, Howard I. Scher, Dana E. Rathkopf, Susan Halabi, Andrew J. Armstrong, David J. Beebe, Menggang Yu, Kaitlin E. Sundling, Mary-Ellen Taplin, Joshua M. Lang
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 21 (2022)
Background Neuroendocrine prostate cancer (NEPC) is an aggressive subtype, the presence of which changes the prognosis and management of metastatic prostate cancer.Methods We performed analytical validation of a Circulating Tumor Cell (CTC) multiplex
Externí odkaz:
https://doaj.org/article/ec5e2f5145314e94b0c25808c0d5eee0
Autor:
Eric Powers, Georgia Sofia Karachaliou, Chester Kao, Michael R. Harrison, Christopher J. Hoimes, Daniel J. George, Andrew J. Armstrong, Tian Zhang
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-13 (2020)
Abstract Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved therapeutics. The recent successful development of poly ADP-ribose polymerase (PARP) inhibitors
Externí odkaz:
https://doaj.org/article/798f2641d2d84fc38d531bd96beebc49